China’s Sinovac coronavirus vaccine candidate shows a safe weaker status

China’s Sinovac coronavirus vaccine candidate shows a safe weaker status

China’s Sinovac coronavirus vaccine

Chinese company Sinovac Biotech Ltd said on Monday that based on preliminary results from early to mid-term trials. Its coronavirus vaccine candidate appears to be safe for the elderly. While the immune response caused by the vaccine is slightly weaker than that of young people.

Read also: Rohingya refugees rescued by Indonesian fishermen after months of voyage at sea

Health officials have been worried:

Health officials have been worried about whether experimental vaccines can safely protect the elderly. Because the immune systems of the elderly usually respond weakly to vaccines. And cannot resist the virus that kills nearly 890,000 people worldwide.

Sinovac media representative Liu Peicheng told Reuters that Sinovac’s candidate CoronaVac launched in May a joint phase 1 and phase 2 trial. Involving 421 participants over 60 years of age, which did not cause serious side effects. The full results have not been released and have not been provided to Reuters.

In the third phase of the trial, four of the eight global vaccines came from China.

For the three groups of participants who took low, medium, and high doses of CoronaVac twice. More than 90% of the antibody levels increased significantly. And the level was slightly lower than that in young subjects. But in line with expectations, Liu Zai The statement said.

CoronaVac has been tested in the final phase of human trials in Brazil and Indonesia. To assess whether its effectiveness and safety are sufficient to obtain regulatory approval and can be used by tens of thousands of people, including approximately 90% of Sinovac employees. Part of China’s emergency vaccination program to protect people at high risk of infection.

Liu said that potential vaccines can remain stable for up to three years of storage. This may provide Sinovac with some advantages in distributing vaccines in areas where cold chain storage is not available.

Liu said that the vaccine readings at 25 degrees Celsius (77 degrees Fahrenheit) for 42 days. 37 degrees Celsius (98.6 degrees Fahrenheit) for 28 days and 2-8 degrees Celsius (35.6-46.4 degrees Fahrenheit) for five months remain acceptable. This fact can be inferred from this estimate. , Without disclosing complete data.

Latest News

Hey, I'm Helen Dunmore an article writer from London Ontario, Canada. I had done a master's in mass communication and M.Phill in political science and attended many College Journalism Broadcast programs where I wrote and won. I previously had attended Humber College for media studies which included writing for television and news. I have written several publications for many news related websites. Have experience more than 7 years, yeah quite a lot for you. I love writing, an expert in article writing. Currently doing article writing for many blog posts and work as an author for many web sites. Reading is my hobby, love books more than anything in my life.

World News